论文部分内容阅读
目的分析胃癌新辅助治疗局部进展期胃癌原发灶病理学完全缓解(pathological complete response,pCR)患者的临床特征。方法筛选哈尔滨医科大学附属肿瘤医院2007年7月1日—2015年12月30日期间胃癌新辅助化疗原发病灶完全缓解的8例患者的临床资料,分析其临床特征;结合目前已有的临床试验结果讨论其个体化治疗策略。结果 8例患者治疗前均为局部进展期胃癌,2例接受SOX方案(替吉奥+奥沙利铂),2例接受XELOX方案(希罗达+奥沙利铂),1例接受TS方案(替吉奥+艾素),1例接受LF方案(希罗达+草铂),1例接受替吉奥+紫杉醇方案,1例接受多西他赛+奥沙利伯方案。结论胃癌新辅助化疗能有效改善胃癌总生存率,但是现有的胃癌新辅助治疗方案的pCR率较低,需要进一步探究新的、高效的化疗方案,实现真正的个体化治疗。
Objective To analyze the clinical features of neoadjuvant gastric cancer treatment for pathological complete response (pCR) patients with locally advanced gastric cancer. Methods The clinical data of 8 patients with complete remission of primary neoadjuvant chemotherapy for stomach cancer from July 1, 2007 to December 30, 2015 in Cancer Hospital of Harbin Medical University were analyzed and their clinical characteristics were analyzed. Combined with the existing clinical The test results discuss their individualized treatment strategies. Results Eight patients had locally advanced gastric cancer before treatment, two received SOX regimen (tiger-plus oxaliplatin), two received XELOX regimen (Xeloda + oxaliplatin) and one received TS regimen (Tegtino + Alzheimer’s), 1 case received LF (Xeloda + Oplatin), 1 received tioglitazone and paclitaxel, and 1 received docetaxel plus oxaliplatin. Conclusion Neoadjuvant chemotherapy for gastric cancer can effectively improve the overall survival rate of gastric cancer. However, the existing neoadjuvant therapy regimens for gastric cancer have a low pCR rate. Therefore, it is necessary to explore new and effective chemotherapy regimens to achieve truly individualized treatment.